Health Care [ 4/12 ] | Life Sciences Tools & Services [ 21/72 ]
NASDAQ | Common Stock
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia.
It operates through, Clinical Services and Pharma Services segments.
The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers.
It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains.
The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services.
It has a strategic alliance agreement and laboratory services agreement with Inivata Limited.
The company was founded in 2001 and is headquartered in Fort Myers, Florida.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 30, 24 | -0.02 Increased by +77.78% | -0.05 Increased by +60.00% |
| Feb 20, 24 | 0.03 Increased by +150.00% | -0.02 Increased by +250.00% |
| Nov 6, 23 | -0.15 Decreased by -5.21% | -0.07 Decreased by -110.43% |
| Aug 8, 23 | -0.05 Increased by +68.75% | -0.11 Increased by +54.55% |
| May 8, 23 | -0.09 Increased by +55.00% | -0.15 Increased by +40.00% |
| Feb 23, 23 | -0.06 Increased by +57.14% | -0.16 Increased by +62.50% |
| Nov 8, 22 | -0.14 Decreased by -75.00% | -0.21 Increased by +33.33% |
| Aug 9, 22 | -0.16 Decreased by -1.50 K% | -0.23 Increased by +30.43% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 151.95 M Increased by +17.99% | -18.52 M Increased by +49.76% | Decreased by -12.19% Increased by +57.42% |
| Jun 30, 23 | 146.92 M Increased by +17.47% | -24.33 M Increased by +31.08% | Decreased by -16.56% Increased by +41.33% |
| Mar 31, 23 | 137.22 M Increased by +17.11% | -30.80 M Increased by +37.67% | Decreased by -22.44% Increased by +46.78% |
| Dec 31, 22 | 138.71 M Increased by +10.32% | -22.69 M Increased by +45.67% | Decreased by -16.36% Increased by +50.75% |
| Sep 30, 22 | 128.78 M Increased by +6.13% | -36.85 M Decreased by -81.11% | Decreased by -28.62% Decreased by -70.64% |
| Jun 30, 22 | 125.07 M Increased by +2.75% | -35.30 M Decreased by -146.53% | Decreased by -28.23% Decreased by -145.28% |
| Mar 31, 22 | 117.17 M Increased by +1.42% | -49.41 M Decreased by -123.42% | Decreased by -42.17% Decreased by -120.30% |
| Dec 31, 21 | 125.73 M Decreased by -0.21% | -41.76 M Decreased by -370.86% | Decreased by -33.21% Decreased by -371.43% |